{"id":59781,"date":"2024-07-31T07:04:50","date_gmt":"2024-07-31T05:04:50","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/bionets-recombinant-pertussis-vaccine-submitted-to-european-medicines-agency-ema\/"},"modified":"2024-07-31T07:04:50","modified_gmt":"2024-07-31T05:04:50","slug":"bionets-recombinant-pertussis-vaccine-submitted-to-european-medicines-agency-ema","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/bionets-recombinant-pertussis-vaccine-submitted-to-european-medicines-agency-ema\/","title":{"rendered":"BioNet\u2019s Recombinant Pertussis Vaccine Submitted to European Medicines Agency (EMA)"},"content":{"rendered":"
\n

\n\u201cMonovalent recombinant acellular pertussis vaccine proven to significantly boost immunity against pertussis\u201d<\/p>\n

<\/a>
<\/a><\/p>\n

LYON, France–(BUSINESS WIRE)–BioNet Europe, the French subsidiary of BioNet, a vaccine manufacturer specializing in the development of genetically engineered vaccines, has announced the submission of a centralized Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its monovalent Recombinant Pertussis Vaccine (RPV).<\/p>\n

\nBioNet\u2019s stand-alone vaccine targets whooping cough, a highly contagious respiratory disease on the steep rise across Europe. This non-combined vaccine is tailored to the persons who require pertussis-only booster vaccination and are up-to-date with their diphtheria and tetanus immunizations.<\/p>\n

\nDr Giuseppe Del Giudice, Director Translational Research at BioNet<\/b>, stated, \u201cBioNet\u2019s recombinant vaccine is designed to provide more effective and longer-lasting immune protection against pertussis than traditional acellular pertussis vaccines. It contains a Pertussis Toxin (PT), the main component responsible for severe pertussis disease, which is inactivated by recombinant technologies rather than chemicals.\u201d<\/i><\/p>\n

\nThese recombinant technologies allow for the preservation of the native structure of the PT, fundamental for the induction of higher immune protection. Currently, no other monovalent or recombinant pertussis vaccines are available in Europe, making BioNet\u2019s RPV a best-in-class vaccine driving significant advancement in public health with the potential to improve acceptance for pertussis immunization.<\/p>\n

\nPhillippe Guillot-Chene, CEO of BioNet Europe,<\/b> added, \u201cWe believe that BioNet\u2019s RPV represents a transformative vaccine for preventing pertussis disease. After receiving the positive feedback from EMA Scientific Advice, we are honored to have our MAA submission validated by the EMA as well.\u201d<\/i><\/p>\n

\nThe safety, immunogenicity and antibody persistence induced after one single booster dose of BioNet\u2019s RPV were demonstrated in numerous randomized clinical trials, notably amongst adults in Australia, adolescents in Switzerland, as well as vulnerable populations such as pregnant women and elderly in Thailand.<\/p>\n

\nThe vaccine is licensed in Asia (under the Pertagen\u00ae trademark) and is included in the pertussis maternal immunization program for pregnant women in Thailand. The MAA of Pertagen\u00ae<\/sup> has also been submitted to the Australian Therapeutic Goods Administration.<\/p>\n

\nAbout BioNet<\/b><\/p>\n

\nBioNet is a vaccine manufacturer specializing in the development of recombinant and mRNA vaccines against respiratory diseases and other global public health threats. BioNet has a strong track record with development and biomanufacturing, having advanced over three proprietary recombinant pertussis vaccines from early R&D to licensure. It currently markets multiple vaccines through its established commercial network. BioNet has been rapidly expanding its operations across Asia, Europe and North America.<\/p>\n

\nForward-Looking Statements<\/b><\/p>\n

\nThis press release contains forward-looking statements relating to BioNet\u2019s business, including regulatory submissions. These statements are based on current expectations as of the date of this press release and involve known and unknown risks and uncertainties that may cause actual results to differ materially. BioNet disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether due to new information, future events, or otherwise.<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia Contacts<\/b>
Europe: Benoit Soubeyrand, bsoubeyrand@bionet.one<\/a>
Asia-Pacific: Laurent Dapremont, laurent.d@bionet-asia.com<\/a>
North America: Bill Cadwallader, bcadwallader@bionet.one<\/a> +1.206.852.0307
\n
Website: bionet.one<\/a> and bionet-asia.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

\u201cMonovalent recombinant acellular pertussis vaccine proven to significantly boost immunity against pertussis\u201d LYON, France–(BUSINESS WIRE)–BioNet Europe, the French subsidiary of BioNet, a vaccine manufacturer specializing in the development of genetically engineered vaccines, has announced the submission of a centralized Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its monovalent Recombinant Pertussis Vaccine … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-59781","6":"format-standard","7":"category-industry"},"yoast_head":"\nBioNet\u2019s Recombinant Pertussis Vaccine Submitted to European Medicines Agency (EMA) - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/bionets-recombinant-pertussis-vaccine-submitted-to-european-medicines-agency-ema\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BioNet\u2019s Recombinant Pertussis Vaccine Submitted to European Medicines Agency (EMA) - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"\u201cMonovalent recombinant acellular pertussis vaccine proven to significantly boost immunity against pertussis\u201d LYON, France–(BUSINESS WIRE)–BioNet Europe, the French subsidiary of BioNet, a vaccine manufacturer specializing in the development of genetically engineered vaccines, has announced the submission of a centralized Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its monovalent Recombinant Pertussis Vaccine ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/bionets-recombinant-pertussis-vaccine-submitted-to-european-medicines-agency-ema\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2024-07-31T05:04:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20240730521754\/en\/2201180\/22\/bionet.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bionets-recombinant-pertussis-vaccine-submitted-to-european-medicines-agency-ema\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bionets-recombinant-pertussis-vaccine-submitted-to-european-medicines-agency-ema\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"BioNet\u2019s Recombinant Pertussis Vaccine Submitted to European Medicines Agency (EMA)\",\"datePublished\":\"2024-07-31T05:04:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bionets-recombinant-pertussis-vaccine-submitted-to-european-medicines-agency-ema\\\/\"},\"wordCount\":517,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bionets-recombinant-pertussis-vaccine-submitted-to-european-medicines-agency-ema\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240730521754\\\/en\\\/2201180\\\/22\\\/bionet.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bionets-recombinant-pertussis-vaccine-submitted-to-european-medicines-agency-ema\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bionets-recombinant-pertussis-vaccine-submitted-to-european-medicines-agency-ema\\\/\",\"name\":\"BioNet\u2019s Recombinant Pertussis Vaccine Submitted to European Medicines Agency (EMA) - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bionets-recombinant-pertussis-vaccine-submitted-to-european-medicines-agency-ema\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bionets-recombinant-pertussis-vaccine-submitted-to-european-medicines-agency-ema\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240730521754\\\/en\\\/2201180\\\/22\\\/bionet.jpg\",\"datePublished\":\"2024-07-31T05:04:50+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bionets-recombinant-pertussis-vaccine-submitted-to-european-medicines-agency-ema\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bionets-recombinant-pertussis-vaccine-submitted-to-european-medicines-agency-ema\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bionets-recombinant-pertussis-vaccine-submitted-to-european-medicines-agency-ema\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240730521754\\\/en\\\/2201180\\\/22\\\/bionet.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240730521754\\\/en\\\/2201180\\\/22\\\/bionet.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bionets-recombinant-pertussis-vaccine-submitted-to-european-medicines-agency-ema\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BioNet\u2019s Recombinant Pertussis Vaccine Submitted to European Medicines Agency (EMA)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BioNet\u2019s Recombinant Pertussis Vaccine Submitted to European Medicines Agency (EMA) - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/bionets-recombinant-pertussis-vaccine-submitted-to-european-medicines-agency-ema\/","og_locale":"en_US","og_type":"article","og_title":"BioNet\u2019s Recombinant Pertussis Vaccine Submitted to European Medicines Agency (EMA) - Pharma Trend","og_description":"\u201cMonovalent recombinant acellular pertussis vaccine proven to significantly boost immunity against pertussis\u201d LYON, France–(BUSINESS WIRE)–BioNet Europe, the French subsidiary of BioNet, a vaccine manufacturer specializing in the development of genetically engineered vaccines, has announced the submission of a centralized Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its monovalent Recombinant Pertussis Vaccine ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/bionets-recombinant-pertussis-vaccine-submitted-to-european-medicines-agency-ema\/","og_site_name":"Pharma Trend","article_published_time":"2024-07-31T05:04:50+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20240730521754\/en\/2201180\/22\/bionet.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/bionets-recombinant-pertussis-vaccine-submitted-to-european-medicines-agency-ema\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/bionets-recombinant-pertussis-vaccine-submitted-to-european-medicines-agency-ema\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"BioNet\u2019s Recombinant Pertussis Vaccine Submitted to European Medicines Agency (EMA)","datePublished":"2024-07-31T05:04:50+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/bionets-recombinant-pertussis-vaccine-submitted-to-european-medicines-agency-ema\/"},"wordCount":517,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/bionets-recombinant-pertussis-vaccine-submitted-to-european-medicines-agency-ema\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20240730521754\/en\/2201180\/22\/bionet.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/bionets-recombinant-pertussis-vaccine-submitted-to-european-medicines-agency-ema\/","url":"https:\/\/pharma-trend.com\/en\/bionets-recombinant-pertussis-vaccine-submitted-to-european-medicines-agency-ema\/","name":"BioNet\u2019s Recombinant Pertussis Vaccine Submitted to European Medicines Agency (EMA) - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/bionets-recombinant-pertussis-vaccine-submitted-to-european-medicines-agency-ema\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/bionets-recombinant-pertussis-vaccine-submitted-to-european-medicines-agency-ema\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20240730521754\/en\/2201180\/22\/bionet.jpg","datePublished":"2024-07-31T05:04:50+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/bionets-recombinant-pertussis-vaccine-submitted-to-european-medicines-agency-ema\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/bionets-recombinant-pertussis-vaccine-submitted-to-european-medicines-agency-ema\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/bionets-recombinant-pertussis-vaccine-submitted-to-european-medicines-agency-ema\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20240730521754\/en\/2201180\/22\/bionet.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20240730521754\/en\/2201180\/22\/bionet.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/bionets-recombinant-pertussis-vaccine-submitted-to-european-medicines-agency-ema\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"BioNet\u2019s Recombinant Pertussis Vaccine Submitted to European Medicines Agency (EMA)"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/59781","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=59781"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/59781\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=59781"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=59781"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=59781"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}